[Treatment of neurogenic diabetes insipidus].
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000150:complications*; D002747:Chlorpropamide / Q000627:therapeutic use*; D002994:Clofibrate / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000209:etiology; D003984:Dibenzazepines / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D011422:Propionates / Q000627:therapeutic use*; D014667:Vasopressins / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D003984:Dibenzazepines; D011422:Propionates; D014667:Vasopressins; D002220:Carbamazepine; D002994:Clofibrate; D002747:Chlorpropamide
Sur les traitements du diabète insipide neurogénique.